Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by T.B. Huq
Total Records ( 2 ) for T.B. Huq
  A. Sarwar , M.S. Rahman , T.B. Huq , K. Biswas , M.I. Hussain , J.F. Chaity , T. Begum , Md. E. Haque , A. Islam and Mst. M. Begum
  Background and Objective: To compare the prevalence of acute vomiting between patients receiving cisplatin as monotherapy or cisplatin in a combination regimen. Materials and Methods: The study was conducted at Delta Hospital Dhaka on a total of 70 patients (44 male and 26 female). The patients received either cisplatin alone or cisplatin with the following chemotherapeutic agents-docetaxel and 5 fluorouracil, docetaxel, etoposide, doxorubicin and capecitabine. The study was conducted in patients receiving chemotherapy for a total of the first 3 cycles. The patients were told to record the number of episodes of vomiting they experienced during the first 24 h after chemotherapy at each cycle. All 70 patients received prechemotherapy antiemetics a combination of 5HT3 receptor antagonist (ondansetron or palanosetron) and dexamethasone prior to chemotherapy. Results: In patients receiving the combination chemotherapy of cisplatin+docetaxel+5 FU experienced the lowest incidence of acute vomiting and cisplatin+capecitabine receiving patients experienced highest incidence of acute vomiting. All the other combination therapy resulted in emesis comparatively similar to that of cisplatin. In all the regimens except for cisplatin+etoposide the percentage of patients experiencing acute vomiting reduced along with progressive cycles. Conclusion: When cisplatin is given in combination regimen except for the combination regimen of cisplatin+capecitabine there is no significant increase in emesis between patients receiving cisplatin alone or in combination therapy.
  A. Tabassum , R.R. Saha , M.S. Rahman , M.A. Nure , R. Karim , A.H.M.R. Imon , M. Maniruzzaman , A.K.L. Kabir , A. Islam , J.F. Chaity , B.C. Adhikary , A. Sarwar , T.B. Huq and Mst. M. Begum
  Background and Objective: Pain management has been an area of a great deal of attention for pharmacists for many years. In this study, we report a study which is designed to investigate how a combination of existing effective drugs performs for the relief of pain management. Materials and Methods: A combined solid dosage containing paracetamol (500 mg) and ibuprofen (150 mg) is developed and tested under an observational analytical study. The performance of this combined oral solid dosage named maxigesic tablet in order to reduce pain is investigated on the basis of European patent specification. This assay is carried out by employing HPLC system with UV detection at 222 nm. Results: The results show the presence of active components to the tune of 112.12% for paracetamol and 101.86% for ibuprofen. The formulated solid dosage is further subjected to separate groups of artificially pain induced mice for a comparative study and it shows more efficacy than single analgesic used in pain management. We observe that the respective potencies for paracetamol and ibuprofenare 98.57 and 102.90%. Conclusion: The characterization of both granules and tablets of newly developed formulation demonstrates significant improvement in results of analytical test that not only met the standard specification, but they also reveal that the combined dosage will improve the product quality, efficacy and patient safety in the long run. This trial also shows a significant difference in the percentage of pain inhibition between the two sets of formulations (single and combination of them).
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility